Exposure to ProtoKinetix’ AAGP™ Maintains Cell Integrity and Cell Function

PROTOKINETIX INC.            (PKTX: OTCBB)
Vancouver, British Columbia, February 15, 2006

ProtoKinetix, Inc. (PKTX), announces today the results of experiments conducted to study the effects of AAGP™ on cellular growth and function. Previous results demonstrated AAGP™ protective activity against harsh stress (such as H2O2 exposure and UV-C radiation) even at low concentrations.

ProteoCell Laboratories have just completed a group of trials to test for possible adverse effects of extended exposure to AAGP™. The first series of tests were designed to examine whether AAGP™ causes any increase in cell growth or change in cell integrity. The skin cells were treated with AAGP™ for 24-hours, washed, and then incubated for up to 5-days. The results show that AAGP™ does not affect cell growth and the cells seem to be morphologically normal, Dr. Samer Hussein, of ProteoCell, states “these results suggest that AAGP™ does not affect cellular integrity or cause any abnormal effects”.

The second group of experiments were set to test for cell functionality and responsiveness. Using one control cell line and another engineered to secrete a recombinant protein, both cell lines were grown with and without AAGP™. The growth media (conditioned media) was collected from all samples after 4-days (total of 4-samples). The media was tested on the control cell lines to check for protein activity using a higher concentration of 15mg/ml. Dr Hussein reports “the results clearly showed that AAGP™ does not affect cell protein secretion and does not change cellular protein activity or mode of action”. He further states that “these observations indicate that the cells remain functional and fully responsive in the presence of AAGP™”.

These experiments demonstrate that extended exposure of AAGP™ to the cells does not affect their cellular growth and the cells remain morphologically normal. Combining this with our previous results suggests that AAGP™ increases cell viability by preventing the cells from dying rather than promote cell growth.

About ProtoKinetix:

ProtoKinetix Inc. is a scientific development company whose mission is the advancement of human health care. The Company’s first entry into the commercial market place will be the launch of the first synthetic age-arresting glycoprotein (AAGP™). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry and molecular biology in order to fast track product development in the areas of cell, tissue and organ preservation.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements.  Some information included in this press release contains statements that are forward-looking.  Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company.  For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

On behalf of the Board of Directors,
Dr. John Todd, President

Company Office:                       
Suite # 1500           
885 West Georgia Street           
Vancouver, BC  V6C 3E8          

Investor Contact:
BCGU, Business Consulting Group Unlimited
In the U.S.:  (888) 772-1288
Outside the U.S.: (760) 230.2300 ext 206